[Updated guidelines for anaphylaxis management - simplified structures for enhanced patient safety].
Lakartidningen · 2025-12-18 · Guideline / consensus
Abstract
The updated Swedish guidelines for anaphylaxis, published by the Swedish Association for Allergology (SFFA) in the autumn of 2024, provide evidence-based recommendations for acute care. The guidelines highlight the importance of rapid intervention and clear diagnostic standards to ensure patient safety. Immediate intramuscular administration of adrenaline is the only evidence-based intervention in the acute phase and should occur without delay or consideration of severity grading. Routine use of corticosteroids is no longer recommended, and severity grading is replaced by NIAID/FAAN criteria. Antihistamines are reserved for post-stabilization. Documentation, observation, and control of serum tryptase levels are essential for continued care, diagnostic accuracy, and long-term management.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Adrenaline · Antihistamines · Cardiovascular drugs · Corticosteroids · Other drugs
Related articles
- Anaphylaxis: Highlights from the practice parameter update. (Cleve Clin J Med, 2022)
- Evidence update for the treatment of anaphylaxis. (Resuscitation, 2021)
- A rapid review of advanced life support guidelines for cardiac arrest associated with anaphylaxis. (Resuscitation, 2021)
- The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. (Allergy, 2007)
- Management of paediatric anaphylaxis: evaluation of clinical practice according to the 2024 Polish Paediatric Society guidelines. (Postepy Dermatol Alergol, 2026)
- Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. (Ann Allergy Asthma Immunol, 2023)